Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696560 | 0.87 | SLC6A4 (0.56) | PYCR1SLC6A4SLC6A2SLC6A3CCR5 | |
| SCHEMBL29888844 | 0.87 | SLC6A4 (0.56) | PYCR1SLC6A4SLC6A2SLC6A3CCR5 | |
| SCHEMBL14174961 | 0.79 | ACHE (0.52) | PYCR1SLC6A4SLC6A2SLC6A3BRD4 | |
| SCHEMBL7602457 | 0.79 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3MEN1ALDH1A1 | |
| SCHEMBL30423333 | 0.79 | PYCR1 (0.53) | PYCR1MEN1ALDH1A1KMT2AHTR2A | |
| SCHEMBL3484403 | 0.79 | PYCR1 (0.53) | PYCR1MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL1125103 | 0.79 | PYCR1 (0.53) | PYCR1MEN1ALDH1A1KMT2AHTR2A | |
| SCHEMBL27494431 | 0.78 | GAA (0.67) | PYCR1SLC6A4SLC6A2SLC6A3BRD4 | |
| SCHEMBL7668799 | 0.77 | PYCR1 (0.51) | PYCR1MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL46431 | 0.77 | PYCR1 (0.51) | PYCR1SLC6A4MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2025-01-30 | — | — | US | disclosed |
| EP-4442685-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou HealZen Therapeutics Co., Ltd. (CN) | 2024-10-09 | — | — | EP | disclosed |
| WO-2023104043-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | 杭州和正医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | PYCR1 1099/4885SLC6A4 4262/4885SLC6A2 4298/4885 |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | BCL2, BAX, BCL2L1 | PYCR1 1423/4885SLC6A4 4875/4885SLC6A2 4859/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | PYCR1 1338/4885SLC6A4 4348/4885SLC6A2 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.